1 / 17

HDL-cholesterol versus apoA -I and Atherosclerosis Regression

HDL-cholesterol versus apoA -I and Atherosclerosis Regression. Prof. Erik Stroes Academic Medical Centre Amsterdam, The Netherlands. Exogenous cholesterol. VLDL. LDL. Chylo-microns. PERIPHERAL TISSUES. INTESTINE. LIVER. Bile excretion. HDL.

wsherman
Télécharger la présentation

HDL-cholesterol versus apoA -I and Atherosclerosis Regression

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HDL-cholesterol versus apoA-Iand Atherosclerosis Regression Prof. Erik Stroes AcademicMedical Centre Amsterdam, The Netherlands

  2. Exogenous cholesterol VLDL LDL Chylo-microns PERIPHERAL TISSUES INTESTINE LIVER Bile excretion HDL HDL-c decreases CV-riskvia ‘Reverse cholesterol transport’ Risk 4.0 4.0 3.0 2.0 2.0 MACROPHAGE 1.0 1.0 0 1.68 0.65 1.17 HDL-c (mmol/L) Kannel WB AJC 52, 1983 – Framingham Study

  3. HDL-c concentration and CV-riskNo association ‘genetic’ HDL-c increase and risk Cohort Atherosclerosis Risk in Communities Study Copenhagen City Heart Study Malmo Diet and Cancer Study, Cardiovascular Cohort Framingham Heart Study Heart Professionals Follow up Study Danish Diet, Cancer, and Health Study Meta-analysis of cohort studies Per 0.03 mmol/L (1 mg/dL) increase in plasma HDL-c Per 0.39 mmol/L (15 mg/dL) increase in plasma HDL-c Epidemiology OR / 0.03 mmol/L HDLc increase Genetics OR / 0.03 mmol/L HDLc increase 0.97 (0.96-0.98) 0.98 (0.98-0.99) 0.97 (0.96-0.98) 0.96 (0.94-0.98) - - 0.98 (0.97-0.98) 0.70 (0.66-0.74) 7x10-18 6x10-13 1x10-6 4x10-6 - - 4x10-36 4x10-36 0.96 (0.86-1.07) 1.09 (0.95-1.26) 0.82 (0.66-1.01) 1.17 (1.00-1.37) 1.84 (0.39-8.62) 1.05 (0.79-1.41) 1.02 (0.95-1.09) 1.28 (0.46-3.61) 0.44 0.21 0.06 0.06 0.16 0.71 0.64 0.64 Voight, Lancet 2012

  4. HDL-c concentration and CV-riskNo association ‘drug-induced’ HDL-c increase and risk • ILLUMINATE Torcetrapib: • HDLc  +72% : CV-death OR +1.25 • DALOUTCOMES Dalcetrapib: • HDLc  +35% : CV-events no change • HPS2-THRIVE Nicotinic acid: • HDLc  +15-25% : CV-events no change • Meta-analysis Briel et al • HDLc  +2-15% : CV-events no change • HDL-c change no longer valid as surrogate • for future CV-risk. Barter, New Engl J Med 2007; Schwartz GG, New Engl J Med 2012 Eur Heart J 2013; Briel, BMJ 2009

  5. HDL-c and Reverse cholesterol transportNo association between HDLc and fecal chol. excretion • HDL-c concentration no longer valid as surrogate • for RCT capacity. Broussea, ATvB 2005

  6. Is apoA-I/HDL involved in RCT?

  7. Decreased ‘Tissue cholesterol efflux’in apoA-I/L178P heterozygotes Holleboom, Stroes J Lipid res 2013

  8. Increased ‘Vessel-wall thickening’in ABCA1 & LCAT- heterozygotes LCAT heterozygotes ABCAI heterozygotes Mean wall area outer wall area Duivenvoorden, Stroes, JACC 2010; Bochem, Stroes, J Lip Res 2013

  9. Number of HDL particles more relevantthan HDL-c concentration Mackey et al., JACC 2012

  10. DO APOA-I - INCREASING STRATEGIES WORK?

  11. apoA-I increase and RCTeffect of rHDL particle infusion (≈ 45mg/kg) AfterInfusion Before Infusion Bile Acids 400 Neutral Sterols HDL-C (mg/dl) 41±7 35% peakIncrease 300 Intestinal Excretion mg/day 200 100 0.0 SG GG LM IN Eriksson, Circ 1999

  12. apoA-I increase and Plaque regressioneffect of rHDL particle infusion (40mg/kg) on peripheral atheroma Shaw, Circ Res 2008

  13. apoA-I and Plaque regressionEffect of ApoAI milano on coronary atheroma P=0.02 REVERSAL ASTEROID APOA-1 Milano 4 4 2.7* 2 Median change in TAV (%) -0.3† -0.8 -4.2 0 Prava 40 mg 18 months Atorva 80 mg 18 months -2 Rosuva 40 mg 24 months -4 ApoA-1 Milano 5 weeks From no change to regression Progression Nissen SE et al. JAMA. 2003 and 2004

  14. apoA-I and Plaque regressionrHDL& delipidated HDL and coronary atheroma Reconstituted HDL (CSL-111) Delipidated HDL (LS-001) Tardiff, JAMA 2007; Waksman, JACC 2010

  15. New apoA-I therapiesCER-001 • composed of recombinant human Apolipoprotein A-I and phospholipid containing Sphingomyelin and dipalmitoyl phosphatidylglycerol • reconstituted charged pre-beta High Density Lipoprotein, mimicking biological properties of natural HDL CER-001: recombinant human apoA-I preB HDL particle

  16. Preliminary results SAMBA studyCER-001 infusion in Subjects with Familial HDL-C deficiency Trial design: Baseline Evaluations Lipoprotein profile Cholesterol Flux MRI Initial Dosing Period CER-001 Day 1 Lipoprotein profile PK and PD Cholesterol Flux Induction Period CER-001 q3 days Day 8 through Day 29 Lipoprotein profile PK and PD MRI Day 29 Maintenance Period CER-001 q2 weeks Week 6 through Week 24 Final Dosing Period CER-001 Week 26 Lipoprotein profile PK and PD MRI Study Drug Dosing Final dose First dose CER-001 8mg/kg Infusions every 3 days CER-001 8mg/kg, Day 1 to Day 29, 9 doses total Infusions every 2 weeks CER001 8mg/kg, 10 doses • Methods: • Safety & lipid profiles • Cholesterol flux: 2H4-sitostanol (oral)13C2-cholesterol (iv) • Vessel wall dimension: 3T-carotid & aorta MRI

  17. Summary Both HDL-chol & apoAI are inversely related to CVD-risk Recent drug trials & genetic studies challenged the protective role of HDL Novel concept:HDL particle number better predictor of CV risk? CER-001, a recombinant human ApoA-I particle: Promotes plasma efflux capacity Promotes fecal cholesterol excretion Reduces carotid wall thicknessin patients with genetic low-HDLc levels Ongoing clinical trials with HDL-c & apoAI elevators will help us determine the value of HDL vs. ApoA-I therapy

More Related